Sharekhan's research report on Ipca Laboratories
Ipca Laboratories Limited’s (Ipca) quarterly performance was better than expectation; Resolution of USFDA hurdles could provide further upside. Strong outlook for the next two-three years; Growth across all business verticals to lead to better profitability. We expect the company to report sales/profit CAGR of 16%/27% over FY2019-FY2021.
Outlook
We maintain our Buy rating on the stock with an unchanged PT of Rs. 1,135.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
